Related references
Note: Only part of the references are listed.Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies
Hao Xie et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Spotlight on aldoxorubicin (INNO-206) and its potential in the treatment of soft tissue sarcomas: evidence to date
Lee D. Cranmer
ONCOTARGETS AND THERAPY (2019)
An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect
Cho Rong Hong et al.
NEOPLASIA (2019)
A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma
Jacob P. Laubach et al.
CLINICAL CANCER RESEARCH (2019)
DMAKO-20 as a New Multitarget Anticancer Prodrug Activated by the Tumor Specific CYP1B1 Enzyme
Jiahua Cui et al.
MOLECULAR PHARMACEUTICS (2019)
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
Kyoji Tsuchikama et al.
PROTEIN & CELL (2018)
Organic CO Prodrugs Activated by Endogenous ROS
Zhixiang Pan et al.
ORGANIC LETTERS (2018)
Drug-DNA adducts as biomarkers for metabolic activation of the nitroaromatic nitrogen mustard prodrug PR-104A
Alessia Stornetta et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Versatile hyaluronic acid modified AQ4N-Cu(II)-gossypol infinite coordination polymer nanoparticles: Multiple tumor targeting, highly efficient synergistic chemotherapy, and real-time self-monitoring
Shihong Shen et al.
BIOMATERIALS (2018)
Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer
Tudor Ciuleanu et al.
CLINICAL LUNG CANCER (2018)
FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer
Kathleen N. Moore et al.
FUTURE ONCOLOGY (2018)
Mechanisms of drug release in pH-sensitive micelles for tumour targeted drug delivery system: A review
Zhe Wang et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2018)
Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy
Hadi Nasiri et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Chemically Defined Antibody- and Small Molecule-Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis
Samuele Cazzamalli et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2018)
An NAD(P)H:Quinone Oxidoreductase 1 Responsive and Self-Immolative Prodrug of 5-Fluorouracil for Safe and Effective Cancer Therapy
Xian Zhang et al.
ORGANIC LETTERS (2018)
Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas
Jun Gong et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
An Endogenous Reactive Oxygen Species (ROS)-Activated Histone Deacetylase Inhibitor Prodrug for Cancer Chemotherapy
Somnath D. Bhagat et al.
CHEMMEDCHEM (2018)
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors
John H. Strickler et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Monoclonal antibodies in cancer immunotherapy
Ilgin Kimiz-Gebologlu et al.
MOLECULAR BIOLOGY REPORTS (2018)
Oncolytic viruses as engineering platforms for combination immunotherapy
Kwame Twumasi-Boateng et al.
NATURE REVIEWS CANCER (2018)
Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications
Nirnoy Dan et al.
PHARMACEUTICALS (2018)
ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence
Jieyi Wang et al.
CLINICAL CANCER RESEARCH (2017)
Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination
Surinder K. Sharma et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
Inhibition of cancer antioxidant defense by natural compounds
Alicja Sznarkowska et al.
ONCOTARGET (2017)
Reactive-Oxygen-Species-Responsive Drug Delivery Systems: Promises and Challenges
Gurusamy Saravanakumar et al.
ADVANCED SCIENCE (2017)
First-in-man dose escalation and pharmacokinetic study of CAP7.1, a novel prodrug of etoposide, in adults with refractory solid tumours
U. Keilholz et al.
EUROPEAN JOURNAL OF CANCER (2017)
Strategies in the designing of prodrugs, taking into account the antiviral and anticancer compounds
Monika A. Lesniewska-Kowiel et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapy
Nicolas Joubert et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Prodrug strategy for cancer cell-specific targeting: A recent overview
Xian Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Spotlight on the delivery of photosensitizers: different approaches for photodynamic-based therapies
Diogo Silva Pellosi et al.
EXPERT OPINION ON DRUG DELIVERY (2017)
αvβ3 integrin-targeted micellar mertansine prodrug effectively inhibits triple-negative breast cancer in vivo
Ping Zhong et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2017)
Chemotherapy agent-unsaturated fatty acid prodrugs and prodrug-nanoplatforms for cancer chemotherapy
Bingjun Sun et al.
JOURNAL OF CONTROLLED RELEASE (2017)
Quantitative modeling of the dynamics and intracellular trafficking of far-red light-activatable prodrugs: implications in stimuli-responsive drug delivery system
Mengjie Li et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2017)
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial
William D. Tap et al.
LANCET ONCOLOGY (2017)
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
Toshihiko Doi et al.
LANCET ONCOLOGY (2017)
Prodrug encapsulated albumin nanoparticles as an alternative approach to manifest anti-proliferative effects of suicide gene therapy
Bulbul Tirkey et al.
MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS (2017)
Polymer Prodrug-Based Nanoreactors Activated by Tumor Acidity for Orchestrated Oxidation/Chemotherapy
Junjie Li et al.
NANO LETTERS (2017)
Strategies and challenges for the next generation of antibody drug conjugates
Alain Beck et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Targeting the tumour microenvironment with an enzyme-responsive drug delivery system for the efficient therapy of breast and pancreatic cancers
Brigitte Renoux et al.
CHEMICAL SCIENCE (2017)
Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression
Jianqin Lu et al.
NATURE COMMUNICATIONS (2017)
Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan
Jhanelle E. Gray et al.
CLINICAL CANCER RESEARCH (2017)
Prodrugs in medicinal chemistry and enzyme prodrug therapies
Raoul Walther et al.
ADVANCED DRUG DELIVERY REVIEWS (2017)
Antibody Directed Enzyme Prodrug Therapy (ADEPT): Trials and tribulations
Surinder K. Sharma et al.
ADVANCED DRUG DELIVERY REVIEWS (2017)
Phase III study of aldoxorubicin vs investigators' choice as treatment for relapsed/refractory soft tissue sarcomas
Sant P. Chawla et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Etodolac and the risk of acute pancreatitis
Kuan-Fu Liao et al.
BIOMEDICINE-TAIWAN (2017)
Enzyme-Responsive Liposomes for the Delivery of Anticancer Drugs
Farnaz Fouladi et al.
BIOCONJUGATE CHEMISTRY (2017)
Progress and problems with the use of suicide genes for targeted cancer therapy
Zahra Karjoo et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia
Talha Badar et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
A Glutathione (GSH)-Responsive Near-Infrared (NIR) Theranostic Prodrug for Cancer Therapy and Imaging
Fanpeng Kong et al.
ANALYTICAL CHEMISTRY (2016)
Cancer Targeted Enzymatic Theranostic Prodrug: Precise Diagnosis and Chemotherapy
Weon Sup Shin et al.
BIOCONJUGATE CHEMISTRY (2016)
Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours
D. Mahalingam et al.
BRITISH JOURNAL OF CANCER (2016)
10-Boronic acid substituted camptothecin as prodrug of SN-38
Lei Wang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
A safe, simple and efficient doxorubicin prodrug hybrid micelle for overcoming tumor multidrug resistance and targeting delivery
Yuling Bao et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Overexpression of NAD(P)H: quinone oxidoreductase 1 (NQO1) and genomic gain of the NQO1 locus modulates breast cancer cell sensitivity to quinones
Christophe Glorieux et al.
LIFE SCIENCES (2016)
Co-delivery of doxorubicin and curcumin by pH-sensitive prodrug nanoparticle for combination therapy of cancer
Yumin Zhang et al.
SCIENTIFIC REPORTS (2016)
A phase 1/2 study of continuous infusion ifosfamide/mesna plus aldoxorubicin in sarcoma patients.
Sant P. Chawla et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility
Elsie M. Williams et al.
BIOCHEMICAL JOURNAL (2015)
Mechanisms of Drug Resistance Related to the Microenvironment of Solid Tumors and Possible Strategies to Inhibit Them
Qian Tan et al.
CANCER JOURNAL (2015)
Exploring hydrogen peroxide responsive thiazolidinone-based prodrugs
Christian Perez et al.
CHEMICAL COMMUNICATIONS (2015)
The rational design of a gemcitabine prodrug with AIE-based intracellular light-up characteristics for selective suppression of pancreatic cancer cells
Haijie Han et al.
CHEMICAL COMMUNICATIONS (2015)
Antibody-targeted drugs and drug resistance-Challenges and solutions
LeeRon Shefet-Carasso et al.
DRUG RESISTANCE UPDATES (2015)
Evolution of targeted therapies in cancer: opportunities and challenges in the clinic
Sam Santhosh et al.
FUTURE ONCOLOGY (2015)
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia
Marina Konopleva et al.
HAEMATOLOGICA (2015)
Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates
Remy Gebleux et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985
Ronald C. Elgersma et al.
MOLECULAR PHARMACEUTICS (2015)
Anti-Lymphoma Efficacy Comparison of Anti-CD20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates
Ondrej Lidicky et al.
MOLECULES (2015)
Glutathione- and pH-responsive nonporous silica prodrug nanoparticles for controlled release and cancer therapy
Zhigang Xu et al.
NANOSCALE (2015)
Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates
Shi Xu
PHARMACEUTICAL RESEARCH (2015)
Leinamycin E1 acting as an anticancer prodrug activated by reactive oxygen species
Sheng-Xiong Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Amplification of oxidative stress by a dual stimuli-responsive hybrid drug enhances cancer cell death
Joungyoun Noh et al.
NATURE COMMUNICATIONS (2015)
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia
Marina Konopleva et al.
HAEMATOLOGICA (2015)
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients
Talia Golan et al.
CANCER MEDICINE (2015)
Synthesis strategies for disulfide bond-containing polymer-based drug delivery system for reduction-responsive controlled release
Lei Liu et al.
FRONTIERS OF MATERIALS SCIENCE (2015)
Utilization of Enzyme-Immobilized Mesoporous Silica Nanocontainers (IBN-4) in Prodrug-Activated Cancer Theranostics
Bau-Yen Hung et al.
NANOMATERIALS (2015)
Glutathione-Responsive Polymeric Micelles Formed by a Biodegradable Amphiphilic Triblock Copolymer for Anticancer Drug Delivery and Controlled Release
Zhigang Xu et al.
ACS BIOMATERIALS SCIENCE & ENGINEERING (2015)
Glutathione-Responsive Polymeric Micelles Formed by a Biodegradable Amphiphilic Triblock Copolymer for Anticancer Drug Delivery and Controlled Release
Zhigang Xu et al.
ACS BIOMATERIALS SCIENCE & ENGINEERING (2015)
Gene-Directed Enzyme Prodrug Therapy
Jin Zhang et al.
AAPS JOURNAL (2015)
Targeted Prodrug Approaches for Hormone Refractory Prostate Cancer
Herve Aloysius et al.
MEDICINAL RESEARCH REVIEWS (2015)
Prodrug Applications for Targeted Cancer Therapy
Irene Giang et al.
AAPS JOURNAL (2014)
pH-Sensitive nano-systems for drug delivery in cancer therapy
Juan Liu et al.
BIOTECHNOLOGY ADVANCES (2014)
Preparation of a Camptothecin Prodrug with Glutathione-Responsive Disulfide Linker for Anticancer Drug Delivery
Zhigang Xu et al.
CHEMISTRY-AN ASIAN JOURNAL (2014)
The Novel Organic Arsenical Darinaparsin Induces MAPK-Mediated and SHP1-Dependent Cell Death in T-cell Lymphoma and Hodgkin Lymphoma Cells and Human Xenograft Models
Dashnamoorthy Ravi et al.
CLINICAL CANCER RESEARCH (2014)
Effects of pharmaceutical PEGylation on drug metabolism and its clinical concerns
Xingwang Zhang et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2014)
Reactive Oxygen Species (ROS) Inducible DNA Cross-Linking Agents and Their Effect on Cancer Cells and Normal Lymphocytes
Wenbing Chen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Prodrugs: A challenge for the drug development
Jolanta B. Zawilska et al.
Pharmacological Reports (2014)
The chemistry, physiology and pathology of pH in cancer
Pawel Swietach et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2014)
Prodrug-based nanoparticulate drug delivery strategies for cancer therapy
Cong Luo et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2014)
Glutathione S-conjugates as prodrugs to target drug-resistant tumors
Emma E. Ramsay et al.
FRONTIERS IN PHARMACOLOGY (2014)
Acetal-Linked Paclitaxel Prodrug Micellar Nanoparticles as a Versatile and Potent Platform for Cancer Therapy
Yudan Gu et al.
BIOMACROMOLECULES (2013)
Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer
S. O. Freytag et al.
GENE THERAPY (2013)
Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38
Vaskor Bala et al.
JOURNAL OF CONTROLLED RELEASE (2013)
Aminoferrocene-Based Prodrugs and Their Effects on Human Normal and Cancer Cells as Well as Bacterial Cells
Paul Marzenell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Site-Specific and Far-Red-Light-Activatable Prodrug of Combretastatin A-4 Using Photo-Unclick Chemistry
Moses Bio et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
A New Strategy for Intracellular Delivery of Enzyme Using Mesoporous Silica Nanoparticles: Superoxide Dismutase
Yi-Ping Chen et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2013)
Mechanistic Study of the Covalent Loading of Paclitaxel via Disulfide Linkers for Controlled Drug Release
Li Yuan et al.
LANGMUIR (2013)
CANCER Calculated treatment
Natalia L. Komarova et al.
NATURE (2013)
Cancer drug resistance: an evolving paradigm
Caitriona Holohan et al.
NATURE REVIEWS CANCER (2013)
Enzyme-responsive nanoparticles for drug release and diagnostics
Roberto de la Rica et al.
ADVANCED DRUG DELIVERY REVIEWS (2012)
A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma
Peter J. Hosein et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Cathepsin B cleavable novel prodrug Ac-Phe-Lys-PABC-ADM enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis An experimental study
Li-Hua Shao et al.
CANCER (2012)
Antibody-Based Immunotherapy of Cancer
Louis M. Weiner et al.
CELL (2012)
Influence of polymer size, liposomal composition, surface charge, and temperature on the permeability of pH-sensitive liposomes containing lipid-anchored poly(2-ethylacrylic acid)
Tingli Lu et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2012)
Synthesis and Biological Evaluation of Antibody Conjugates of Phosphate Prodrugs of Cytotoxic DNA Alkylators for the Targeted Treatment of Cancer
Robert Yongxin Zhao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Aminoferrocene-Based Prodrugs Activated by Reactive Oxygen Species
Helen Hagen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Prodrug enzymes and their applications in image-guided therapy of cancer: tracking prodrug enzymes to minimize collateral damage
Marie-France Penet et al.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2012)
ROS-activated anticancer prodrugs: a new strategy for tumor-specific damage
Xiaohua Peng et al.
THERAPEUTIC DELIVERY (2012)
Prodrugs for improving tumor targetability and efficiency
Rubi Mahato et al.
ADVANCED DRUG DELIVERY REVIEWS (2011)
Prodrug-based intracellular delivery of anticancer agents
L. Bildstein et al.
ADVANCED DRUG DELIVERY REVIEWS (2011)
Trastuzumab Emtansine (T-DM1): A Novel Agent for Targeting HER2+ Breast Cancer
Howard A. Burris et al.
CLINICAL BREAST CANCER (2011)
Prodrugs for Targeted Tumor Therapies: Recent Developments in ADEPT, GDEPT and PMT
Lutz F. Tietze et al.
CURRENT PHARMACEUTICAL DESIGN (2011)
Anticancer Prodrugs: An Overview of Major Strategies and Recent Developments
Silvia Arpicco et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2011)
Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery
Ru Cheng et al.
JOURNAL OF CONTROLLED RELEASE (2011)
Hydrogen Peroxide Inducible DNA Cross-Linking Agents: Targeted Anticancer Prodrugs
Yunyan Kuang et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2011)
Enzyme-mediated hydrolytic activation of prodrugs
Yan-hui Yang et al.
ACTA PHARMACEUTICA SINICA B (2011)
Reactive oxygen species in cancer
Geou-Yarh Liou et al.
FREE RADICAL RESEARCH (2010)
Sitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma
Erik H. P. van Putten et al.
FUTURE ONCOLOGY (2010)
Targeted Enzyme Prodrug Therapies
N. Schellmann et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2010)
Emerging applications of stimuli-responsive polymer materials
Martien A. Cohen Stuart et al.
NATURE MATERIALS (2010)
Concise Review: Nanoparticles and Cellular Carriers-Allies in Cancer Imaging and Cellular Gene Therapy?
Catherine Tang et al.
STEM CELLS (2010)
Glutathione Transferases as Targets for Cancer Therapy
Paolo Ruzza et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2009)
Determination of glutathione and glutathione disulfide in biological samples: An in-depth review
Peter Monostori et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2009)
A preclinical assessment of the safety and biodistribution of an adenoviral vector containing the herpes simplex virus thymidine kinase gene (Cerepro®) after intracerebral administration
Gillian Langford et al.
JOURNAL OF GENE MEDICINE (2009)
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Dunyaporn Trachootham et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Metabolic activation of the antitumor drug 5-(Aziridin-1-yl)-2,4-diniti-obenzamide (CB1954) by NO synthases
Alexia Chandor et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2008)
Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: Results of a phase I study
Mark R. Albertella et al.
CLINICAL CANCER RESEARCH (2008)
Recent trends in targeted anticancer prodrug and conjugate design
Yashveer Singh et al.
CURRENT MEDICINAL CHEMISTRY (2008)
An ICT-Based approach to ratiometric fluorescence imaging of hydrogen peroxide produced in living cells
Duangkhae Srikun et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2008)
Kinetic and structural characterisation of Escherichia coli nitroreductase mutants showing improved efficacy for the prodrug substrate CB1954
Paul R. Race et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Antibody-directed enzyme prodrug therapy (ADEPT) for cancer
Kenneth D. Bagshawe
EXPERT REVIEW OF ANTICANCER THERAPY (2006)
Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N
A. Yakkundi et al.
CANCER GENE THERAPY (2006)
Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes
AA Gabizon et al.
CLINICAL CANCER RESEARCH (2006)
Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms
WY Wu et al.
CANCER RESEARCH (2006)
Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth doxorubicin with less toxicity
CF Albright et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma
JP Braybrooke et al.
CLINICAL CANCER RESEARCH (2005)
Glutathione metabolism and its implications for health
GY Wu et al.
JOURNAL OF NUTRITION (2004)
Enzyme-catalyzed activation of anticancer prodrugs
M Rooseboom et al.
PHARMACOLOGICAL REVIEWS (2004)
Polymeric micelle for tumor pH and folate-mediated targeting
ES Lee et al.
JOURNAL OF CONTROLLED RELEASE (2003)
A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours
RJ Francis et al.
BRITISH JOURNAL OF CANCER (2002)
Elucidation of the mechanism of incorporation of insulin in controlled release systems based on complexation polymers
M Morishita et al.
JOURNAL OF CONTROLLED RELEASE (2002)
Potentiation of antitumor immunity by antibody-directed enzyme prodrug therapy
BM Chen et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material
SD Webley et al.
BRITISH JOURNAL OF CANCER (2001)
Activation of antibacterial prodrugs by peptide deformylase
YM Wei et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2000)
Efficient clearance of poly(ethylene glycol)modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy
TL Cheng et al.
BIOCONJUGATE CHEMISTRY (2000)
Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect
SM Stribbling et al.
HUMAN GENE THERAPY (2000)
In vitro and in vivo efficacy of acid-sensitive transferrin and albumin doxorubicin conjugates in a human xenograft panel and in the MDA-MB-435 mamma carcinoma model
F Kratz et al.
JOURNAL OF DRUG TARGETING (2000)
Share Paper
